Since October 1, forty newly created cryptocurrency wallets have withdrawn a total of 9,458 Bitcoin (BTC) from Wintermute, valued at approximately $772 million. This significant movement of assets highlights ongoing activity and potential liquidity concerns within Wintermute, a notable player in digital asset markets. Investors should monitor further developments as these withdrawals may impact market dynamics or signal internal issues at Wintermute.
The recent withdrawals of 9,458 Bitcoin from Wintermute provide context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 02:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 36 rose and 13 fell today. Notable movers include SAND at Rp938 with a -4.41% change and 60% sell order activity, COTI at Rp202 with a +3.90% change and 84% sell order activity, and VET at Rp130 with a +3.33% change and 88% sell order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
